Therapeutic Asset Ratings
396 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
ly4175408
Endometrial Cancer
Eli Lilly and Company
P1
CC
(41)
ly4175408
Small Cell Lung Carcinoma
Eli Lilly and Company
P1
CC
(41)
ly4257496
Endometrial Cancer
Eli Lilly and Company
P1
CC
(41)
ly4257496
Gastric Neoplasm
Eli Lilly and Company
P1
CC
(41)
ly4337713
Gastric Neoplasm
Eli Lilly and Company
P1
CC
(41)
Selpercatinib
Colon Carcinoma
Eli Lilly and Company
P1/2
CC
(41)
Carboplatin
Metastatic Solid Tumor
Eli Lilly and Company
P1
CC
(40)
Colulintide
Obesity Disorder
Eli Lilly and Company
P1
CC
(40)
Drospirenone
Obesity Disorder
Eli Lilly and Company
P1
CC
(40)
NISOSTIROTIDE
Obesity Disorder
Eli Lilly and Company
P1
CC
(40)
Tersolisib
Breast Cancer
Eli Lilly and Company
P1/2
CC
(40)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Metastatic Neoplasm
Eli Lilly and Company
P1
C
(39)
Itraconazole
Colorectal Neoplasm
Eli Lilly and Company
P1
C
(39)
Itraconazole
Ovarian Neoplasm
Eli Lilly and Company
P1
C
(39)
Loxo-338
B-Cell Non-Hodgkin Lymphoma
Eli Lilly and Company
P1
C
(39)
Loxo-338
Non-Hodgkin Lymphoma
Eli Lilly and Company
P1
C
(39)
Loxo-435
Metastatic Neoplasm
Eli Lilly and Company
P1
C
(39)
ly3410738
Cholangiocarcinoma
Eli Lilly and Company
P1
C
(39)
ly3410738
Glioma
Eli Lilly and Company
P1
C
(39)
ly3885125
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company
P1
C
(39)
ly4052031
Urinary Bladder Carcinoma
Eli Lilly and Company
P1
C
(39)
ly4086940
Type 2 Diabetes Mellitus
Eli Lilly and Company
P1
C
(39)
ly4101174
Urinary Bladder Carcinoma
Eli Lilly and Company
P1
C
(39)
ly4152199 - iv
B-Cell Non-Hodgkin Lymphoma
Eli Lilly and Company
P1
C
(39)
ly4152199 - iv
Non-Hodgkin Lymphoma
Eli Lilly and Company
P1
C
(39)
Showing 301 to 325 of 396 assets
Previous
Page 13 of 16
Next
